Comparison of Outcomes Using Bare Metal Versus Drug-Eluting Stents in Coronary Artery Disease Patients With and Without Human Immunodeficiency Virus Infection

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 216-222

  Ren, Xiushui ^a   Trilesskaya, Marina ^a   Kwan, Damon M ^a   Nguyen, Kim ^a   Shaw, Richard E ^a   Hui, Peter Y ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVASCULARIZATION; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK ASSESSMENT; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67649392545     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.036     Document Type: Article

References (30)

1. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., and Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., and Russell M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Schofer J., Schluter M., Gershlick A.H., Wijns W., Garcia E., Schampaert E., and Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
4. Holmes Jr. D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong S.C., Midei M., Snead D., and Kuntz R.E. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
5. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., Gomez-Hospital J.A., Alfonso F., Hernandez-Antolin R., Goicolea J., Banuelos C., Escaned J., Moreno R., Fernandez C., Fernandez-Aviles F., and Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
6. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., Cutlip D.E., Fahy M., Pocock S.J., Mehran R., and Leon M.B. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
7. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
8. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
9. Luepker R.V., Apple F.S., Christenson R.H., Crow R.S., Fortmann S.P., Goff D., Goldberg R.J., Hand M.M., Jaffe A.S., Julian D.G., Levy D., Manolio T., Mendis S., Mensah G., Pajak A., Prineas R.J., Reddy K.S., Roger V.L., Rosamond W.D., Shahar E., Sharrett A.R., Sorlie P., and Tunstall-Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 108 (2003) 2543-2549
10. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
11. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., and Leon M.B. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
12. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., Thiebaut R., Morfeldt L., De Wit S., Pradier C., Calvo G., Law M.G., Kirk O., Phillips A.N., and Lundgren J.D. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
13. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., Wood K.C., Greenberg A.E., and Janssen R.S. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
14. Hsue P.Y., Giri K., Erickson S., MacGregor J.S., Younes N., Shergill A., and Waters D.D. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109 (2004) 316-319
15. Segev A., Cantor W.J., and Strauss B.H. Outcome of percutaneous coronary intervention in HIV-infected patients. Cathet Cardiovasc Interv 68 (2006) 879-881
16. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
17. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187 (2003) 1534-1543
18. Bloomfield Rubins H., Davenport J., Babikian V., Brass L.M., Collins D., Wexler L., Wagner S., Papademetriou V., Rutan G., and Robins S.J. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 (2001) 2828-2833
19. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
20. Colombo A., Orlic D., Stankovic G., Corvaja N., Spanos V., Montorfano M., Liistro F., Carlino M., Airoldi F., Chieffo A., and Di Mario C. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 107 (2003) 2178-2180
21. Elezi S., Kastrati A., Neumann F.J., Hadamitzky M., Dirschinger J., and Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 98 (1998) 1875-1880
22. Kastrati A., Schomig A., Elezi S., Schuhlen H., Dirschinger J., Hadamitzky M., Wehinger A., Hausleiter J., Walter H., and Neumann F.J. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30 (1997) 1428-1436
23. Kobayashi Y., De Gregorio J., Kobayashi N., Akiyama T., Reimers B., Finci L., Di Mario C., and Colombo A. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 34 (1999) 651-659
24. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
25. Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Mangino M., Mayer B., Dixon R.J., Meitinger T., Braund P., Wichmann H.E., Barrett J.H., Konig I.R., Stevens S.E., Szymczak S., Tregouet D.A., Iles M.M., Pahlke F., Pollard H., Lieb W., Cambien F., Fischer M., Ouwehand W., Blankenberg S., Balmforth A.J., Baessler A., Ball S.G., Strom T.M., Braenne I., Gieger C., Deloukas P., Tobin M.D., Ziegler A., Thompson J.R., and Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
26. Sugerman R.W., Church J.A., Goldsmith J.C., and Ens G.E. Acquired protein S deficiency in children infected with human immunodeficiency virus. Pediatr Infect Dis J 15 (1996) 106-111
27. Hadigan C., Meigs J.B., Rabe J., D'Agostino R.B., Wilson P.W., Lipinska I., Tofler G.H., and Grinspoon S.S. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 86 (2001) 939-943
28. Reingold J., Wanke C., Kotler D., Lewis C., Tracy R., Heymsfield S., Tien P., Bacchetti P., Scherzer R., Grunfeld C., and Shlipak M. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 48 (2008) 142-148
29. Mintz G.S., Popma J.J., Hong M.K., Pichard A.D., Kent K.M., Satler L.F., and Leon M.B. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 78 (1996) 18-22
30. Sabin C.A., Worm S.W., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M., D'Arminio Monforte A., Friis-Moller N., Kirk O., Pradier C., Weller I., Phillips A.N., and Lundgren J.D. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008) 1417-1426